MARBURG KASALLIGI - EPIDEMIOLOGIYA, PATOGENEZ, KLINIK KECHISHI, DIAGNOSTIKA, DAVOLASH VA PROFILAKTIKA

Авторы

  • Obdоlova Dilаrom Maxmudovna, Sotlikova Jonigul Raximovna, Raximova Sayyora Omangaldiyevna Author

Ключевые слова:

Marburg kasalligi, Marburg virusi, gemorragik isitma, Filoviridae, sitokin bo'roni, endotelial shikastlanish, postekspozitsion profilaktika, zoonoz, RT-PCR, epidemiya.

Аннотация

Marburg kasalligi (Marburg virusli gemorragik isitmasi, MVGI) — Filoviridae oilasiga mansub Marburg virusi (MARV) chaqiradigan o'tkir antropozoonoz gemorragik isitma bo'lib, letalligi tarixi davomida 24%dan 88%gacha ko'rsatkichlarga erishgan eng xavfli yuqumli kasalliklardan biri hisoblanadi. Jahon sog'liqni saqlash tashkiloti (WHO) mazkur kasallikni jahon xavfsizligiga potentsial tahdid soluvchi ustuvor patogen sifatida A toifali biologik xavf ro'yxatiga kiritgan. Mazkur obzor maqolaning maqsadi 2019–2025-yillarda nashr etilgan zamonaviy ilmiy manbalar asosida Marburg kasalligining epidemiologiyasi, etiologiyasi, rezervuari, patogenezi, klinik kechishi, diagnostikasi, davolash usullari va profilaktikasiga oid ma'lumotlarni tizimli tahlil qilishdan iborat. Izlash PubMed, Scopus, WHO va CDC ma'lumotlar bazalarida amalga oshirildi; 20 dan ortiq manba tahlilga kiritildi. Natijalarda Marburg virusining mevali yarasalar (Rousettus aegyptiacus) bilan zoonotik bog'liqligi, endotelial shikastlanish va sitokin bo'roniga asoslangan patogenetik mexanizm, gemorragik sindrom hamda ko'p a'zolar yetishmovchiligining klinik xususiyatlari, RT-PCR va ELISA asosida tashxis qo'yish strategiyasi, shuningdek, hozirgi kunda mavjud bo'lgan eksperimental terapiya va infeksiya nazorati bo'yicha chora-tadbirlar ko'rsatib berildi. Xulosa tariqasida, erta tashxis, qat'iy kontaktni nazorat qilish va vaksinatsiya sohasidagi izlanishlarni jadallashtirishning global sog'liqni saqlash xavfsizligi uchun hal qiluvchi ahamiyati ta'kidlandi.

Библиографические ссылки

1. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389(10068):505–518.

2. World Health Organization. Marburg virus disease — Guinea [disease outbreak news]. Geneva: WHO; 2021 [cited 2025 Aug 15]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/marburg-virus-disease-guinea-2021

3. World Health Organization. Marburg virus disease [fact sheet]. Geneva: WHO; 2024 [cited 2025 Aug 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease

4. World Health Organization. Marburg virus disease — Equatorial Guinea and United Republic of Tanzania [outbreak updates]. Geneva: WHO; 2023.

5. Nyakarahuka L, Shoemaker TR, Balinandi S, Chemos G, Ojwang J, Tumusiime A, et al. Marburg virus disease outbreak in Kween District Uganda, 2017: Epidemiological and laboratory findings. PLoS Negl Trop Dis. 2019;13(3):e0007257.

6. Slenczka W, Klenk HD. Forty years of Marburg virus. J Infect Dis. 2007;196(Suppl 2):S131–S135.

7. Centers for Disease Control and Prevention. Marburg hemorrhagic fever (Marburg HF): infection control [Internet]. Atlanta: CDC; 2024 [cited 2025 Aug 25]. Available from: https://www.cdc.gov/marburg/

8. Bhatt KH, Bhatt ML. Filoviridae: structure, replication and pathogenesis. J Virol Methods. 2022;304:114508.

9. Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science. 2016;351(6279):1393–1398.

10. Faul EJ, Wanjalla CN, Suthar MS, Bloodgood B, Bhargava M, Bhavnani SK, et al. Marburg virus evades interferon responses by a mechanism distinct from Ebola virus. PLoS Pathog. 2019;15(12):e1008170.

11. Amman BR, Jones ME, Sealy TK, Uebelhoer LS, Schuh AJ, Bird BH, et al. Oral shedding of Marburg virus in experimentally infected Egyptian fruit bats. J Wildl Dis. 2019;55(2):357–366.

12. Mtonga W, Tembo J, Kayira M, et al. Haematological and biochemical parameters in Marburg virus disease patients: a systematic review. Trop Med Infect Dis. 2023;8(7):348.

13. Paweska JT, Scholz P, Vervoerd DW. Clinical features of Marburg virus disease in southern Africa. In: Klenk HD, Feldmann H, editors. Marburg and Ebola Viruses. Berlin: Springer; 2020. p. 187–216.

14. Sow MS, Keita MT, Fofana DB, Koivogui A, Barry A, Guéckédougou V, et al. Laboratory diagnostics during the first Marburg virus outbreak in Guinea. PLoS Negl Trop Dis. 2022;16(11):e0010903.

15. Röltgen K, Bühler MM, Huber M, Müller NJ, Karrer U, Schreiber PW, et al. Evaluation of ELISA and rapid diagnostic tests for Marburg virus detection during a simulated outbreak. J Clin Virol. 2021;140:104870.

16. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385.

17. Cross RW, Woolsey C, Longini IM, Geisbert JB, Borisevich V, Agans KN, et al. Comprehensive genomic sequencing and phylogenetic analysis of a monoclonal antibody cocktail (MR191) active against Marburg virus. PLoS Pathog. 2023;19(4):e1011281.

18. Zingman BS, Boffito M. Progress toward a Marburg vaccine: emerging data from phase I/II trials. Lancet Infect Dis. 2024;24(3):e177–e182.

19. Woolsey C, Cross RW, Agans KN, Beadles S, Geisbert JB, Foster SL, et al. Postexposure protection of non-human primates against Marburg virus disease with a recombinant vesicular stomatitis virus–based vaccine. J Infect Dis. 2021;223(12):2048–2055.

Опубликован

2026-04-20

Выпуск

Раздел

Articles

Как цитировать

MARBURG KASALLIGI - EPIDEMIOLOGIYA, PATOGENEZ, KLINIK KECHISHI, DIAGNOSTIKA, DAVOLASH VA PROFILAKTIKA. (2026). Journal of Multidisciplinary Education, Science and Technology, 1(2), 16-31. https://universaljournalnews.uz/index.php/mest/article/view/16